Poor patent quality, biosimilars, third-party disputes, Brexit and more from our pharma and biotech event 17 Feb 18
Last week, life sciences patent professionals from around the world gathered at London’s Hallam Conference Centre for IAM’s second annual Pharma and Biotech IP Summit – the first ever IAM event to be held on UK home turf. Delegates – and there were twice as many in attendance than were at our first summit in Munich in 2016 – were treated to insightful presentations and discussions by seasoned in-house and private practice professionals on a range of key legal, strategic and policy-related topics.
Want to read more?
Register to access two of our subscriber-only articles per month
Subscribe for unlimited access to articles, in-depth analysis and research from the IAM experts
What our customers are saying
Straight talk on key IP issues, IAM aims to provide executive managers with the business perspective that often gets lost in technical jargon and legal details.
Senior vice president of intellectual property
The Nielsen Company
Subscribe to receive access to the full range of premium business intelligence, insights and analysis, as well as our IP directories, guides and daily news.
Register for more free content
- Read more IAM blogs and articles
- Receive the editor's weekly review by email